Home HIV	FAQ My Amedeo About	Flying Publisher
	Amedeo Prize 2008 The 21 Finalists

Malaria

Free Subscription Articles published in Vaccine Retrieve available abstracts of 43 articles: HTML format

Single Articles

March 2008
1. KESTER KE , Cummings JF, Ockenhouse CF, Nielsen R, et al
   Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naive adults at the Walter Reed Army Institute of Research.
   Vaccine. 2008;.
   PubMed     Related articles    Abstract available
   
   
   January 2008
2. BUENO LL , Fujiwara RT, Soares IS, Braga EM, et al
   Direct effect of Plasmodium vivax recombinant vaccine candidates AMA-1 and MSP-1(19) on the innate immune response.
   Vaccine. 2008;.
   PubMed     Related articles    Abstract available
   
   
   November 2007
3. SACARLAL J , Aponte JJ, Aide P, Mandomando I, et al
   Safety of the RTS,S/AS02A malaria vaccine in Mozambican children during a Phase IIb trial.
   Vaccine. 2007;.
   PubMed     Related articles    Abstract available
   
   
   
4. LEBLANC R , Vasquez Y, Hannaman D, Kumar N, et al
   Markedly enhanced immunogenicity of a Pfs25 DNA-based malaria transmission-blocking vaccine by in vivo electroporation.
   Vaccine. 2007;.
   PubMed     Related articles    Abstract available
   
   
   
5. MIURA K , Orcutt AC, Muratova OV, Miller LH, et al
   Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines.
   Vaccine. 2007;.
   PubMed     Related articles    Abstract available   Free Full Text
   
   
   
6. BERGMANN-LEITNER ES , Duncan EH, Leitner WW, Neutzner A, et al
   C3d-defined complement receptor-binding peptide p28 conjugated to circumsporozoite protein provides protection against Plasmodium berghei.
   Vaccine. 2007;25:7732-6.
   PubMed     Related articles    Abstract available
   
   
   October 2007
7. HUI G , Hashimoto C
   The requirement of CD80, CD86, and ICAM-1 on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine.
   Vaccine. 2007;.
   PubMed     Related articles    Abstract available
   
   
   August 2007
8. BEJON P , Mwangi T, Lowe B, Peshu N, et al
   Clearing asymptomatic parasitaemia increases the specificity of the definition of mild febrile malaria.
   Vaccine. 2007;.
   PubMed     Related articles    Abstract available
   
   
   July 2007
9. DOBANO C , Widera G, Rabussay D, Doolan DL, et al
   Enhancement of antibody and cellular immune responses to malaria DNA vaccines by in vivo electroporation.
   Vaccine. 2007;.
   PubMed     Related articles    Abstract available
   
   
   
10. MOORTHY V , Reed Z, Smith PG
    Measurement of malaria vaccine efficacy in phase III trials: Report of a WHO consultation.
    Vaccine. 2007;25:5115-23.
    PubMed     Related articles    Abstract available
    
    
    June 2007
11. OPHORST OJ , Radosevic K, Klap JM, Sijtsma J, et al
    Increased immunogenicity of recombinant Ad35-based malaria vaccine through formulation with aluminium phosphate adjuvant.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    May 2007
12. KESTER KE , McKinney DA, Tornieporth N, Ockenhouse CF, et al
    A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naive adults.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
13. MULLEN GE , Aebig JA, Dobrescu G, Rausch K, et al
    Enhanced antibody production in mice to the malaria antigen AMA1 by CPG 7909 requires physical association of CpG and antigen.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
14. DEVI YS , Mukherjee P, Yazdani SS, Shakri AR, et al
    Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
15. ROJAS CARABALLO J , Delgado G, Rodriguez R, Patarroyo MA, et al
    The antigenicity of a Plasmodium vivax reticulocyte binding protein-1 (PvRBP1) recombinant fragment in humans and its immunogenicity and protection studies in Aotus monkeys.
    Vaccine. 2007;25:3713-21.
    PubMed     Related articles    Abstract available
    
    
    March 2007
16. POLHEMUS ME , Magill AJ, Cummings JF, Kester KE, et al
    Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naive adults at the Walter Reed Army Institute of Research.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
17. BERMUDEZ A , Reyes C, Guzman F, Vanegas M, et al
    Synthetic vaccine update: Applying lessons learned from recent SPf66 malarial vaccine physicochemical, structural and immunological characterization.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
18. QIAN F , Wu Y, Muratova O, Zhou H, et al
    Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: A strategy for enhancing immunogenicity of malaria vaccine candidates.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
19. SHARMA SK , Gupta C, Dwivedi V, Misra-Bhattacharya S, et al
    Prophylactic potential of liposomized integral membrane protein of Plasmodium yoelii nigeriensis against blood stage infection in BALB/c mice.
    Vaccine. 2007;25:2103-11.
    PubMed     Related articles    Abstract available
    
    
    January 2007
20. MOORTHY G , Ramasamy R
    Mucosal immunisation of mice with malaria protein on lactic acid bacterial cell walls.
    Vaccine. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
21. LOGAN GJ , Wang L, Zheng M, Cunningham SC, et al
    AAV vectors encoding malarial antigens stimulate antigen-specific immunity but do not protect from parasite infection.
    Vaccine. 2007;25:1014-22.
    PubMed     Related articles    Abstract available
    
    
    November 2006
22. ZHANG Q , Xue X, Qu L, Pan W, et al
    Construction and evaluation of a multistage combination vaccine against malaria.
    Vaccine. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
23. BILLAUD JN , Peterson D, Lee BO, Maruyama T, et al
    Advantages to the use of rodent hepadnavirus core proteins as vaccine platforms.
    Vaccine. 2006;.
    PubMed     Related articles    Abstract available   Free Full Text
    
    
    October 2006
24. GIRARD MP , Reed ZH, Friede M, Kieny MP, et al
    A review of human vaccine research and development: Malaria.
    Vaccine. 2006;.
    PubMed     Related articles    Abstract available
    
    
    September 2006
25. PATTNAIK P , Shakri AR, Singh S, Goel S, et al
    Immunogenicity of a recombinant malaria vaccine based on receptor binding domain of Plasmodium falciparum EBA-175.
    Vaccine. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
26. RAMJANEE S , Robertson JS, Franke-Fayard B, Sinha R, et al
    The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials.
    Vaccine. 2006;.
    PubMed     Related articles    Abstract available
    
    
    August 2006
27. AHUJA S , Pettersson F, Moll K, Jonsson C, et al
    Induction of cross-reactive immune responses to NTS-DBL-1alpha/x of PfEMP1 and in vivo protection on challenge with Plasmodium falciparum.
    Vaccine. 2006;24.
    PubMed     Related articles    Abstract available
    
    
    
28. HERMSEN CC , Verhage DF, Telgt DS, Teelen K, et al
    Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial.
    Vaccine. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
29. LI S , Locke E, Bruder J, Clarke D, et al
    Viral vectors for malaria vaccine development.
    Vaccine. 2006;.
    PubMed     Related articles    Abstract available
    
    
    July 2006
30. STEWART VA , Walsh DS, McGrath SM, Kester KE, et al
    Cutaneous delayed-type hypersensitivity (DTH) in a multi-formulation comparator trial of the anti-falciparum malaria vaccine candidate RTS,S in rhesus macaques.
    Vaccine. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
31. STEWART VA , McGrath SM, Walsh DS, Davis S, et al
    Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A.
    Vaccine. 2006;.
    PubMed     Related articles    Abstract available
    
    
    June 2006
32. IMOUKHUEDE EB , Berthoud T, Milligan P, Bojang K, et al
    Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men.
    Vaccine. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
33. SIRIMA SB , Nebie I, Ouedraogo A, Tiono AB, et al
    Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthethic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa.
    Vaccine. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
34. MIAO J , Li X, Liu Z, Xue C, et al
    Immune responses in mice induced by prime-boost schemes of the Plasmodium falciparum apical membrane antigen 1 (PfAMA1)-based DNA, protein and recombinant modified vaccinia Ankara vaccines.
    Vaccine. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
35. BONNET S , Petres S, Holm I, Fontaine T, et al
    Soluble and glyco-lipid modified baculovirus Plasmodium falciparum C-terminal merozoite surface protein 1, two forms of a leading malaria vaccine candidate.
    Vaccine. 2006;.
    PubMed     Related articles    Abstract available
    
    
    May 2006
36. GIERSING BK , Dubovsky F, Saul A, Denamur F, et al
    Potency assay design for adjuvanted recombinant proteins as malaria vaccines.
    Vaccine. 2006;24:4264-70.
    PubMed     Related articles    Abstract available
    
    
    
37. PEEK LJ , Brandau DT, Jones LS, Joshi SB, et al
    A systematic approach to stabilizing EBA-175 RII-NG for use as a malaria vaccine.
    Vaccine. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
38. WALSH DS , Gettayacamin M, Leitner WW, Lyon JA, et al
    Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02A.
    Vaccine. 2006;24:4167-78.
    PubMed     Related articles    Abstract available
    
    
    March 2006
39. BEJON P , Mwacharo J, Kai OK, Todryk S, et al
    Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area.
    Vaccine. 2006;.
    PubMed     Related articles    Abstract available
    
    
    
40. DRUILHE P , Sauzet JP, Sylla K, Roussilhon C, et al
    Worms can alter T cell responses and induce regulatory T cells to experimental malaria vaccines.
    Vaccine. 2006;.
    PubMed     Related articles   
    
    
    
41. SACHDEVA S , Mohmmed A, Dasaradhi PV, Crabb BS, et al
    Immunogenicity and protective efficacy of Escherichia coli expressed Plasmodium falciparum merozoite surface protein-1(42) using human compatible adjuvants.
    Vaccine. 2006;24:2007-16.
    PubMed     Related articles    Abstract available
    
    
    
42. RAMASAMY R , Yasawardena S, Zomer A, Venema G, et al
    Immunogenicity of a malaria parasite antigen displayed by Lactococcus lactis in oral immunisations.
    Vaccine. 2006;.
    PubMed     Related articles    Abstract available
    
    
    November 2005
43. SEDEGAH M , Rogers WO, Belmonte A, Belmonte M, et al
    Vaxfectintrade mark enhances immunogenicity and protective efficacy of P. yoelii circumsporozoite DNA vaccines.
    Vaccine 2005;.
    PubMed     Related articles    Abstract available
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Bernd Sebastian Kamps website.    Design: